{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:48:26Z","timestamp":1787032106057,"version":"build-2736575974"},"reference-count":21,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.5582\/ddt.2025.01106","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:07:53Z","timestamp":1765404473000},"page":"404-413","source":"Crossref","is-referenced-by-count":1,"title":["A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride\/sodium ferrous citrate (5-ALA-HCl\/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids"],"prefix":"10.5582","volume":"19","author":[{"given":"Remi","family":"Sumiyoshi","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kamisawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hori","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Hattori","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiki","family":"Hikake","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan."},{"name":"Department of Rheumatology, St. Francis Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Division of Immunology and Rheumatology, Hamamatsu University School of Medicine, Hamamatsu, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kadavath S, Efthimiou P. Adult-onset Still&apos;s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015; 47:6-14.","DOI":"10.3109\/07853890.2014.971052"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F. Efficacy and safety of therapies for Still&apos;s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still&apos;s disease. Ann Rheum Dis. 2024; 83:1731-1747.","DOI":"10.1136\/ard-2024-225854"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kirino Y, Takeno M, Iwasaki M, Ueda A, Ohno S, Shirai A, Kanamori H, Tanaka K, Ishigatsubo Y. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still&apos;s disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther. 2005; 7:R616-624.","DOI":"10.1186\/ar1721"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kirino Y, Kawaguchi Y, Tada Y, <i>et al<\/i>. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still&apos;s disease: A multicenter retrospective study. Mod Rheumatol. 2018; 28:858-864.","DOI":"10.1080\/14397595.2017.1422231"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nishio Y, Fujino M, Zhao M, Ishii T, Ishizuka M, Ito H, Takahashi K, Abe F, Nakajima M, Tanaka T, Taketani S, Nagahara Y, Li XK. 5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1. Int Immunopharmacol. 2014; 19:300-307.","DOI":"10.1016\/j.intimp.2014.02.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Morse D, Choi AM. Heme oxygenase-1: the &quot;emerging molecule&quot; has arrived. Am J Respir Cell Mol Biol. 2002; 27:8-16.","DOI":"10.1165\/ajrcmb.27.1.4862"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujino M, Nishio Y, Ito H, Tanaka T, Li XK. 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. Int Immunopharmacol. 2016; 37:71-78.","DOI":"10.1016\/j.intimp.2015.11.034"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hou J, Cai S, Kitajima Y, Fujino M, Ito H, Takahashi K, Abe F, Tanaka T, Ding Q, Li XK. 5-Aminolevulinic acid combined with ferrous iron induces carbon monoxide generation in mouse kidneys and protects from renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2013; 305:F1149-1157.","DOI":"10.1152\/ajprenal.00275.2013"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Terada Y, Inoue K, Matsumoto T, <i>et al.<\/i> 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats <i>in vitro<\/i> and <i>in vivo<\/i>. PLoS One. 2013; 8:e80850.","DOI":"10.1371\/journal.pone.0080850"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hou J, Zhang Q, Fujino M, Cai S, Ito H, Takahashi K, Abe F, Nakajima M, Tanaka T, Xu J, Zou H, Ding Q, Li XK. 5-Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice <i>via<\/i> induction of regulatory cells. J Heart Lung Transplant. 2015; 34:254-263.","DOI":"10.1016\/j.healun.2014.09.037"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310:2191-2194.","DOI":"10.1001\/jama.2013.281053"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sumiyoshi R, Koga T, Kamisawa O, <i>et al.<\/i> A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride\/Sodium Ferrous Citrate (5-ALA-HCl\/SFC) for Patients With Adult-Onset Still&apos;s Disease (AOSD) Refractory to Corticosteroids. Cureus. 2025; 17:e90354.","DOI":"10.7759\/cureus.90354"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hara T, Koda A, Nozawa N, Ota U, Kondo H, Nakagawa H, Kamiya A, Miyashita K, Itoh H, Nakajima M, Tanaka T. Combination of 5-aminolevulinic acid and ferrous ion reduces plasma glucose and hemoglobin A1c levels in Zucker diabetic fatty rats. FEBS Open Bio. 2016; 6:515-528.","DOI":"10.1002\/2211-5463.12048"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, Sumida T. Nationwide epidemiological survey of 169 patients with adult Still&apos;s disease in Japan. Mod Rheumatol. 2015; 25:393-400.","DOI":"10.3109\/14397595.2014.974881"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ruperto N, Brunner HI, Quartier P, <i>et al.<\/i> Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367:2396-2406.","DOI":"10.1056\/NEJMoa1205099"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Vojinovic J, Damjanov N, D&apos;Urzo C, Furlan A, Susic G, Pasic S, Iagaru N, Stefan M, Dinarello CA. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011; 63:1452-1458.","DOI":"10.1002\/art.30238"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T. Tocilizumab in patients with adult-onset still&apos;s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018; 77:1720-1729.","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Campbell NK, Fitzgerald HK, Dunne A. Regulation of inflammation by the antioxidant haem oxygenase 1. Nat Rev Immunol. 2021; 21:411-425.","DOI":"10.1038\/s41577-020-00491-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ryter SW. Heme Oxgenase-1, a Cardinal Modulator of Regulated Cell Death and Inflammation. Cells. 2021; 10:515.","DOI":"10.3390\/cells10030515"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Koga T, Sumiyoshi R, Tsuji Y, Kodama K, Endo Y, Furukawa K, Kawakami A. Efficacy and safety of 5-aminolevulinic acid in adult-onset Still&apos;s disease: A preclinical study in mice and a pilot study in humans. Clin Immunol. 2023; 257:109846.","DOI":"10.1016\/j.clim.2023.109846"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sumiyoshi R, Koga T, Shimizu T, Sato S, Tashiro S, Hosogaya N, Yamamoto H, Kawakami A. Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease: Study protocol for clinical trial (SPIRIT compliant). Medicine (Baltimore). 2020; 99:e22708.","DOI":"10.1097\/MD.0000000000022708"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01106\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:20:03Z","timestamp":1768018803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01106\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01106","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01106"}}